朱书雷

发布者:何靖宇发布时间:2024-04-09浏览次数:801


个人简介:


朱书雷,华东师范大学药学院副教授,硕士生导师。目前从事抗肿瘤药物以及衰老疾病药物的设计与递送工作,致力于开发抗肿瘤药物和衰老相关疾病药物应用的新方法和新技术,解决药物脱靶与在靶毒性问题。通过构建新型酶活前药疗法,成功开发出若干新型高效的临床候选药物,已与多个医药公司达成合作,实现科研成果转化。目前,共同设计开发的Linker-Payload平台已应用于包括前药(prodrug)抗体药物偶联物(ADC)、小分子药物偶联物(SMDC)、多肽药物偶联物(PDC)等体系。基于该平台的抗体药物偶联物,已经获得多个临床批件。另外,有多个候选分子处于临床前研究中。以第一/通讯作者在J. Control. Release, Asian J. Pharm. Sci., J. Med. Chem., Eur. J. Med. Chem.等期刊发表SCI论文18篇;申请发明专利10项;主持和参与国家自然科学基金青年基金项目1项和企业横向合作项目若干项;担任J. Med.Chem., Eur. J. Med. Chem., Int. J. Nanomed.等期刊审稿人。兼任中国药学会会员;中国化学会高级会员;上海市药学会会员等。


联系方式:


slzhu@chem.ecnu.edu.cn


联系地址:


上海市普陀区中山北路3663号理科大楼B430


教育背景:

2015-092020-07,华东师范大学,有机化学,博士(导师:吕伟 研究员)


工作经历:

2023-10至今,华东师范大学,人工智能新药创智中心,副研究员

2020-072023-09,华东师范大学,博士后(合作导师:吕伟 研究员)


研究方向:


1.新型抗体药物偶联物

2.衰老疾病相关新药发现

3.新型药物递送系统



科研项目:


1.国家自然科学基金委员会,青年科学基金项目,基于胞外HSP90配体的药物偶联物传递系统,821040002020-012022-12

2.企业合作项目,抗体偶联药物linker-payload研究,2023-122024-12

3.企业合作项目,ADC毒素-喜树碱类分子联合研究,2022-072026-12

4.企业合作项目,新型连接子技术联合研究,2024-052029-12

5.企业合作项目,氘代喜树碱类分子联合研究,2022-122030-12


部分代表性论文:

  1. Li, Y. L.; Cheng, Z. Y.; Zhou, W.; Wang, L.; Li, X. M.; Xia, G. X.; Lu, W.;Zhu, S. L.*Synthesis and evaluation of homocamptothecin antibody-drug conjugates for cancer treatment.European Journal of Medicinal Chemistry,2024,

  2. Jiang, X.;Zhu, L. Y.; Wei, Q. Y.; Lu, W.; Yu, J. H.;Zhu, S. L.* Enhancing SN38 prodrug delivery using a self-immolative linker and endogenous albumin transport.Journal of Controlled Release, 2024, 369, 622-629.

  3. Lu, Y., Huang, Y., Jin, J., Yu, J., Lu, W.,Zhu, S. L.*. Design, synthesis, and biological evaluation of cathepsin B cleavage albumin-binding SN38 prodrug in breast cancer.Bioorganic Chemistry, 2024,147, 107370.

  4. Cao, Y. T.;Shen, Q. Q.; Ding, M. Y.; Lu, W.;Zhu, S. L.* Development of HSP90 inhibitors-SN38 conjugates for cancer treatment.Bioorganic Chemistry, 2023, 137, 106582.

  5. Ding, M., Zhu, Q., Lu, W.,Zhu, S. L.*. Design and synthesis of multivalent drug delivery system with CA IX inhibitors as ligands.Bioorganic & Medicinal Chemistry, 2023, 93, 117456.

  6. Sun, L.; Zhang, J. F.; Zhou, J. E.; Wang, J.; Wang, Z. H.; Luo, Y. Y.;Zhu, S. L.*; Yang, F.; Tang, J.; Lu, W.; Wang, Y. T.; Yu, L.; Yan, Z. Q*. Monitoring thein vivosiRNA release from lipid nanoparticles based on the fluorescence resonance energy transfer principle.Asian Journal of Pharmaceutical Sciences, 2023, 18, 100769.

  7. Ding, M. Y.; Shao, Y. Y.; Sun, D. W.; Meng, S. R.; Zang, Y.; Zhou, Y. B.; Li, J.; Lu, W.;Zhu, S. L.* Design, synthesis, and biological evaluation of BRD4 degraders.Bioorganic & Medicinal Chemistry, 2022, 78, 117134.

  8. Zhu, S. L.; Liu, J. Y.; Xiao, D. H.; Wang, P. P.; Ma, J. K.; Hu, X. B.; Fu, J. F.; Zhou, Y. B.*; Li, J.*; Lu, W*. Design, synthesis, and biological evaluation of Wee1 kinase degraders. European Journal of Medicinal Chemistry,2022, 243, 114786.

  9. Zhu, S. L.; Lu, Y. X.; Jin, J. Y.*; Yu, J. H.; Lu, W*. An HSP90 inhibitor based fluorescent probe for selective tumor targeting.Dyes and Pigments, 2021, 196, 109783.

  10. Zhu, S. L.; Li, Y. L.; Huang, Y. S.; Zhang, M. M.; Gu, X. F.; He, Y.; Liu, H. C.; Ma, M. L.*; Lu, W*. Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging.Journal of Materials Chemistry B, 2020, 8, 1878-1896.

  11. Zhu, S. L.; Yu, X. M.; He, Y.; Ma, M. L.*; Lu, W*. Synthesis and fluorescent studies of a low molecular weight rotor for living cancer cell imaging.Dyes and Pigments, 2020, 178, 108353.

  12. Zhu, S. L.; Shen, Q. Q.; Gao, Y. L.; Wang, L.; Fang, Y. F.*; Chen, Y.; Lu, W*. Design, synthesis and biological evaluation of HSP90 inhibitor-SN38 conjugates for targeted drug accumulation.Journal of Medicinal Chemistry, 2020, 63, 5421-5441.

  13. Zhen, Z.#;Zhu, S. L.#; Jin, J. Y.; Wang, L.*; Lu, W*. A water-soluble probe with p-hydrobenzyl quaternary ammonium linker for selective imaging in senescent cells.Analytica Chimica Acta, 2020, 1133, 99-108.

  14. Lu, Y. X.; Sun, D. W.; Xiao, D. H.; Shao, Y. Y.; Su, M. B.; Zhou, Y. B.; Li, J.;Zhu, S. L.*; Lu, W*. Design, synthesis and biological evaluation of HDAC degraders with CRBN E3 ligase ligands.Molecules, 2021, 26, 7241.

  15. He, T. T.;Zhu, S. L.*; Lu, W*. Design, synthesis and biological evaluation of 4-(1H-1,2,3-triazol-1-yl)benzamides as HSP90 inhibitors.Molecular Diversity, 2023, 27, 239-248.

  16. Ding, M. Y.; Shen, Q. Q.; Lu, W*;Zhu, S. L.*. Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment.Molecular Diversity, 2023, 1-20.

  17. Zhang, Y.; Ding, M.; Wang, L.; Yin, S.; Zhang, L.; Cao, X.;Zhu, S. L.*; Yang, T. Synthesis and biological evaluation of novel quaternary ammonium antibody drug conjugates based on camptothecin derivatives.Plos one, 2023,18(12), e0292871.

  18. Huang, Y.; Zhang, W.; Xu, Y.;Zhu, S. L.; Wu, Y.; Chen, T.; Yu, J. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: An intelligent tumor-targeted delivery nanoplatform.International Journal of Pharmaceutics, 2020, 580, 119250.

  19. Cheng, Z.; Huang, Y.; Shao, P.; Wang, L.;Zhu, S. L.; Yu, J.; Lu, W. Hypoxia-activated albumin-binding exatecan prodrug for cancer therapy.ACS omega, 2021,7(1), 1082-1089.